51. Implementation of High-Sensitivity and Point-of-Care Cardiac Troponin Assays into Practice: Some Different Thoughts
- Author
-
Corinne R. Fantz, Fred S. Apple, and Paul Collinson
- Subjects
medicine.medical_specialty ,Cardiac troponin ,Coronavirus disease 2019 (COVID-19) ,Point-of-Care Systems ,Clinical Biochemistry ,Myocardial Infarction ,Clinical Chemistry Tests ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Troponin T ,Limit of Detection ,medicine ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Intensive care medicine ,Point of care ,Biochemistry, medical ,Mini-Reviews ,biology ,business.industry ,SARS-CoV-2 ,Biochemistry (medical) ,Troponin I ,COVID-19 ,medicine.disease ,Troponin ,Patient management ,biology.protein ,Biomarker (medicine) ,Myocardial infarction diagnosis ,business ,Biomarkers - Abstract
Background The primary role of the International Federation of Clinical Chemistry (IFCC) Committee on Clinical Application of Cardiac Bio-Markers (C-CB) is to provide educational materials about cardiac biomarker use, emphasizing high-sensitivity cardiac troponin assays. Content This mini-review, regarding high-sensitivity cardiac and point-of-care troponin assays, addresses 1) new IFCC C-CB/AACC Academy laboratory practice recommendations; 2) new and updated concepts from the Fourth Universal Definition of Myocardial Infarction; 3) the role of point-of-care assays in practice and research; 4) regulatory challenges concerning point-of-care assays; e) testing in the COVID-19 world. Summary Implementation of high-sensitivity cardiac troponin assays makes a difference now and into the future in clinical practice and research. Providing point-of-care high-sensitivity cardiac troponin assays and optimizing studies to allow clearance of these assays by regulatory agencies, in a timely fashion, may provide improved patient management and outcomes.
- Published
- 2020
- Full Text
- View/download PDF